Collected Dataset / SCQM_axSpA_Followup_2006

The population is composed of all patients with ankylosing spondylitis (AS) or other forms of spondyloarthritis (SpA) with predominantly axial disease according to the opinion of the treating rheumatologist.

Information about disease characteristics, concomitant treatments, laboratory values, comorbidities and adverse drug events was collected. In addition, information about socioeconomic (education level), smoking status, treatment (type of medications, exact dosage and the start and stop dates), disease state and quality of life (using the Bath Ankylosing Spondylitis Disease Activity Index, the Bath Ankylosing Spondylitis Functional Index, the Short Form 36 Health Survey, the EuroQol 5-domain and EQ visual analog scale questionnaires, numerical rating scales of nocturnal pain) was collected. Clinical evaluation included the physician’s global assessment of disease activity on a numerical rating scale (range 0–10). The physical examination included the presence of peripheral arthritis, enthesitis (Maastricht Ankylosing Spondylitis Enthesitis Score; range 0–13) with a definition of pressure intensity to be applied on the depicted entheses, the presence of dactylitis, measurement of height, weight, chest expansion, finger-to-floor distance, as well as spinal mobility according to the Bath Ankylosing Spondylitis Metrology Index. Radiographs were collected. Spine and sacroiliac joint X-Rays were performed every 2-3 years at the discretion of the treating physician. Biosample(s) timing is left at the discretion of the treating physician. As a first aim of the biobank, at least one sample for each patient should be collected.